Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H21N3O5 |
Molecular Weight | 311.3336 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1O)C(=O)OCCCCNC(N)=N
InChI
InChIKey=WNGSUWLDMZFYNZ-UHFFFAOYSA-N
InChI=1S/C14H21N3O5/c1-20-10-7-9(8-11(21-2)12(10)18)13(19)22-6-4-3-5-17-14(15)16/h7-8,18H,3-6H2,1-2H3,(H4,15,16,17)
Molecular Formula | C14H21N3O5 |
Molecular Weight | 311.3336 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Leonurine (LN) is a natural alkaloid extracted from Herba leonuri which is used in Chinese traditional medicine and possesses anti-inflammatory properties. Leonurine has potential as a therapeutic agent for rheumatoid arthritis and might be a promising therapeutic compound to treat osteoclast-related diseases, such as osteoporosis. These effects are achieved through the inhibition of NF-κB and mitogen-activated protein kinase pathways. In addition, it was found that leonurine protects BBB integrity by regulating the HDAC4/NOX4/MMP-9 tight junction pathway and could therfeore represent a new class of potential drugs against the acute onset of ischemic stroke. In experiments on mice with adenomyosis leonurine attenuated generalized hyperalgesia, however, the mechanism responsible for alleviating pain was not readily apparent.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28690765
Curator's Comment: Leonurine (also named SCM-198) could decrease infarct volume and improve neurological deficit by protecting against blood-brain barrier (BBB) breakdown
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25708053/ |
|||
Target ID: HDAC4/NOX4/MMP-9 tight junction pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/28690765 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of leonurine on the activity of creatine kinase. | 2004 Dec |
|
Protective effects of leonurine in neonatal rat hypoxic cardiomyocytes and rat infarcted heart. | 2009 Jul |
|
[Determination of leonurine in leonurus granule and extractum by UPLC]. | 2009 Jun |
|
Herba leonurine attenuates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells. | 2009 Jun 10 |
|
4-Guanidino-n-butyl syringate (Leonurine, SCM 198) protects H9c2 rat ventricular cells from hypoxia-induced apoptosis. | 2009 Nov |
|
Magnesium Lithospermate B Protects Cardiomyocytes from Ischemic Injury Via Inhibition of TAB1-p38 Apoptosis Signaling. | 2010 |
|
Neuroprotective effects of leonurine on ischemia/reperfusion-induced mitochondrial dysfunctions in rat cerebral cortex. | 2010 |
|
Development and validation of an UPLC-DAD-MS method for the determination of leonurine in Chinese motherwort (Leonurus japonicus). | 2010 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28389633
mice with adenomyosis: group 1 received a low-dose (30 mg/kg body weight) leonurine treatment; group 2 received a high-dose (60 mg/kg body weight) leonurine
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27823628
Leonurine could obviously attenuate the spontaneous excitatory postsynaptic current amplitude and frequency on pyramidal neurons. In in vitro study, there were control group, OGD group, OGD+ 100µM leonurin group, and OGD+ 10µM donepezil group.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:39:13 GMT 2023
by
admin
on
Sat Dec 16 01:39:13 GMT 2023
|
Record UNII |
09Q5W34QDA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24697-74-3
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY | |||
|
m6765
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
LEONURINE
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY | |||
|
DTXSID70179434
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY | |||
|
09Q5W34QDA
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY | |||
|
C013587
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY | |||
|
161464
Created by
admin on Sat Dec 16 01:39:13 GMT 2023 , Edited by admin on Sat Dec 16 01:39:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |